The occurrence of epidermal growth factor receptor (EGFR) mutation and the emergence of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have changed the treatment prospect of NSCLC, and EGFR-TKIs are now commonly used in the first or subsequent lines of therapy for NSCLC patients with EGFR mutations [2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.